221 CRESCENT STREET, WALTHAM, MA
Viridian Therapeutics Completes $250 Million Convertible Notes Offering
Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Investor Presentation
Annual Report to Security Holders
Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Viridian Therapeutics Enters Underwriting Agreement for $251.35M Offering
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus